Edgewise Therapeutics, INC Form 4 insider transactions

Edgewise Therapeutics' Chief Business Officer, Behrad Derakhshan, reported routine equity compensation grants and a sell-to-cover transaction for tax obligations.

Edgewise Therapeutics CFO R. Michael Carruthers reported recent transactions involving company common stock, including RSU vesting, a sell-to-cover tax sale, and new equity grants.

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported routine stock transactions including RSU vesting, a sell-to-cover tax sale, and new equity grants.

Edgewise Therapeutics CEO Kevin Koch disclosed the vesting of restricted stock units, a tax-related stock sale, and substantial new equity grants including RSUs and stock options.

Edgewise Therapeutics' Chief Medical Officer, Joanne M. Donovan, reported the vesting of restricted stock units, a related tax-withholding sale, and new equity grants.

Edgewise Therapeutics, Inc. Director Jonathan C. Fox reported the acquisition of 858 shares of common stock through a restricted stock unit grant as part of his director compensation.

Edgewise Therapeutics, Inc. Director Laura Brege was granted 30,000 stock options with an exercise price of $14.68, vesting by June 2026.

Edgewise Therapeutics, Inc. Director Badreddin Edris was granted 30,000 stock options with an exercise price of $14.68, vesting by June 2026.

Jonathan C Fox, a Director at Edgewise Therapeutics, Inc., reported the acquisition of 30,000 stock options with an exercise price of $14.68, vesting by June 2026.

Edgewise Therapeutics, Inc. Director Arlene Morris was granted 30,000 stock options with an exercise price of $14.68, vesting on June 16, 2026, or earlier.

Edgewise Therapeutics, Inc. Director Jonathan D. Root has been granted 30,000 stock options with an exercise price of $14.68, set to vest by mid-2026.

Peter A. Thompson, a Director and 10% Owner of Edgewise Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $14.68, set to vest by June 2026.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, reports the acquisition and disposal of company stock and restricted stock units to cover tax obligations.

John R. Moore, General Counsel of Edgewise Therapeutics, sold shares to cover statutory tax withholding obligations related to vesting Restricted Stock Units.

CEO Kevin Koch reports the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Joanne M. Donovan, CMO of Edgewise Therapeutics, reports the acquisition and disposition of common stock and restricted stock units to cover tax obligations.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, sold shares to cover tax obligations related to vesting Restricted Stock Units.

R. Michael Carruthers, CFO of Edgewise Therapeutics, reports the acquisition and disposal of company stock related to restricted stock units and tax obligations.

Director Peter A. Thompson reports purchases of Edgewise Therapeutics (EWTX) common stock through indirect holdings via OrbiMed funds.

OrbiMed Advisors, a significant shareholder in Edgewise Therapeutics, has increased its holdings through purchases in a recent public offering.

Director Jonathan C. Fox acquired 559 shares of Edgewise Therapeutics, Inc. on April 1, 2025, through restricted stock units.

Alan Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised stock options and sold 200 shares of common stock at an average price of $30.02.

Edgewise Therapeutics CEO Kevin Koch exercised stock options and sold 100 shares of common stock at $30 per share, while also reporting beneficial ownership through family trusts and an LLC.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised stock options and sold shares of common stock on February 5th and 6th, 2025, according to a recent SEC Form 4 filing.

CEO Kevin Koch exercised stock options and sold shares of Edgewise Therapeutics, Inc. on February 5th and 6th, 2025, according to a Form 4 filing.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, exercised stock options and sold 10,000 shares of common stock on February 5, 2025.

Edgewise Therapeutics' Chief Medical Officer, Joanne M. Donovan, exercised stock options and sold 25,000 shares of common stock on January 28, 2025, under a pre-arranged 10b5-1 trading plan.

Robert Blaustein, Chief Development Officer of Edgewise Therapeutics, was granted 160,000 stock options and 30,000 restricted stock units on January 21, 2025.

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and sold 100,000 shares of common stock on December 30, 2024.

Marc Semigran, Chief Development Officer of Edgewise Therapeutics, exercised stock options and sold shares on December 24, 2024, according to a Form 4 filing.